Contacts
Info
Reliable dividend payers popular with income-focused investors. AI-powered earnings call analysis for Income & Dividends (INCOME). Two AI hosts break down quarterly results, key metrics, and market implications in digestible...
show more
Reliable dividend payers popular with income-focused investors. AI-powered earnings call analysis for Income & Dividends (INCOME). Two AI hosts break down quarterly results, key metrics, and market implications in digestible podcast episodes.
show less
Episodes & Posts
Episodes
Posts
AI-generated content
29 AUG 2026 · More earnings analysis: https://betafinch.com
Groups: RETAIL (https://betafinch.com/groups/RETAIL), INCOME (https://betafinch.com/groups/INCOME)
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're digging into McDonald's second quarter 2026 results, and there's a lot to unpack — some real strategic news alongside a leadership change. Before we get into it, quick note: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
JORDAN: Yeah, and this one's juicy, Alex — because it's not the usual "everything's great" call. McDonald's actually came out and said, in Chris Kempczinski's words, "we don't have a strategy problem, we simply didn't execute."
ALEX: Right, so let's start with the numbers. Systemwide sales grew 4% in constant currency, global comparable sales up 1.3%. Adjusted EPS came in at $3.38, up 5% on a constant currency basis. Solid, but not spectacular.
JORDAN: And the real story is the U.S. — comp sales grew just 0.8% in the quarter, which was below expectations. International actually carried the day here, with IOM up 1.5% and the international developmental licensed markets up 1.9%, led by Japan posting its tenth straight quarter of positive guest counts.
ALEX: So what actually went wrong in the U.S.? CFO Ian Borden broke it into pieces. They launched this new "everyday affordable price" menu — 10 items under $3 — in late April, but execution was spotty. Only about 60 to 65% of restaurants actually followed the recommended pricing.
JORDAN: And here's the kicker — to fund that value push, they pulled back on digital offers and killed the Buy One, Add One for a dollar promotion, which apparently really annoyed their most loyal, high-frequency customers. Kempczinski flat-out called it "a bad trade."
ALEX: Management said that alone accounted for about two-thirds of the traffic miss. The rest came down to their FIFA-themed marketing campaign in June underperforming expectations.
JORDAN: There was also this operational overload problem — Chris painted a great picture of it, basically saying "put yourself in a restaurant manager's shoes." You've got K-Pop Demon Hunters merchandise going up, then three weeks later you're flipping the value menu, then a brand-new beverage platform launches, then FIFA. Crew members are getting whiplash, service times went up, satisfaction scores went down.
ALEX: It's a good reminder that even a company with McDonald's scale and marketing muscle can trip over its own to-do list. Too much "new" at once, poorly sequenced.
JORDAN: Right, and it bled into July too — Borden mentioned U.S. comps were actually slightly negative to start Q3. So this isn't fully behind them yet.
ALEX: Now here's where it gets interesting — there's a leadership shakeup. Skye Anderson, previously COO of McDonald's USA, is stepping in as the new President of McDonald's U.S., effective immediately. Joe Erlinger, who ran the U.S. business for nearly seven years, is leaving the company.
JORDAN: Chris was pretty deliberate about framing this as a planned transition, not a panic move — he name-checked Anderson's 26-year track record, including a stint leading the U.S. West zone where she drove over 30% comp sales growth. But the timing, right after a rough quarter, is obviously going to raise eyebrows.
ALEX: On the brighter side — beverages. McDonald's launched a new beverage platform in the U.S., Canada, and Germany in May, and early results are beating expectations. Higher checks, strong food attachment, and more than half the traffic is coming after the lunch rush — which is exactly the low-volume window they want to fill.
JORDAN: They're also leaning into Red Bull Energizers rolling out in the U.S. soon, and Australia just launched the platform in mid-July. This seems like a l This episode includes AI-generated content.
AI-generated content
31 JUL 2026 · More earnings analysis: https://betafinch.com
Groups: RETAIL (https://betafinch.com/groups/RETAIL), INCOME (https://betafinch.com/groups/INCOME)
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown of the companies moving the market. Today we're digging into Colgate-Palmolive's second quarter 2026 results. Before we get into it — quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
JORDAN: And there was a lot to dig into here, Alex. This was a "good news, but with an asterisk" kind of quarter.
ALEX: Exactly. Let's start with the headline numbers. Colgate delivered organic sales growth in four of five geographic divisions and three of four product categories. Gross margin expanded 100 basis points to a level that's up 90 basis points versus last quarter. Free cash flow was up 18%, and they returned $1.4 billion to shareholders. CFO Stan Sutula even raised the full-year gross margin guidance to roughly flat for the year — up from a prior expectation of a decline.
JORDAN: That raise is notable because it's not just a fluke — management said it's coming from real execution: revenue growth management, productivity, favorable mix, plus a modest one-time tariff refund benefit that they don't expect to repeat.
ALEX: Right, and CEO Noel Wallace was pretty upfront that this was a global story — emerging markets were the star again, up mid-single digits, led by India, Brazil, Mexico, and China.
JORDAN: India in particular jumped out to me — double-digit growth in the quarter. And Latin America was strong too: Brazil up high single digits, Mexico mid-single digits, with a nice balance between pricing and volume. They're also lapping last year's Colgate Total reformulation issue, and those shares are coming back nicely, especially in Brazil.
ALEX: But — and here's the asterisk — the U.S. business was the soft spot. Wallace didn't sugarcoat it, saying the North America team was "disappointed" with the quarter.
JORDAN: Yeah, a few things stacked up there. May saw a sharp category slowdown tied to spiking gas prices hitting consumer confidence. There was heightened competitive activity, and retailers pulled back inventory — so shipments came in below actual consumption, roughly consumption flat versus shipments down 3%.
ALEX: There was a great exchange with an analyst about that exact gap between what tracking data shows and what Colgate actually reports. Wallace admitted part of it is inventory destocking, but he was candid that they also lost a bit of share in untracked channels — so it's not purely a data mismatch, there's real competitive pressure in there too.
JORDAN: What I liked was the specificity of the fix. It's not just "we'll try harder" — they identified select price gaps versus competitors in certain retailers and categories, and they're stepping up advertising in the back half, which is a real financial commitment given ad spend is already sitting near 20-year highs as a percentage of sales.
ALEX: One analyst actually pushed on that — is 14% of sales the right ad spend level, or is that masking soft ROI given organic growth is only running 2 to 3%? Wallace's answer was basically: their data and digital measurement capabilities have improved a lot, ROI on digital and social specifically looks strong, and ultimately it's about long-term brand health, not just quarterly efficiency.
JORDAN: Let's talk pets, because Hill's continues to be a genuine bright spot. Ex-private label, organic growth of 4%, well ahead of a category that's basically flat. The therapeutic and premium science-led segments are doing the heavy lifting there.
ALEX: And there's a longer-term storyline brewing with the Prime brand and this new "Fresh" launch — single-protein, vet-recommended, science-first position This episode includes AI-generated content.
AI-generated content
30 JUL 2026 · More earnings analysis: https://betafinch.com
Groups: INCOME (https://betafinch.com/groups/INCOME)
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Altria Group's second quarter 2026 results. I'm Alex, joined as always by Jordan. And before we get into it — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
JORDAN: Good to be here, Alex. And there's actually a lot to unpack this quarter — Altria raised guidance, but the story underneath it is more nuanced than the headline suggests.
ALEX: Let's start with the numbers. Adjusted diluted EPS came in at $1.48 for the quarter, up 2.8%. For the first half of the year, that's $2.80, up a healthier 4.9%. And on the back of that first-half strength, Altria narrowed — and actually raised the low end of — full-year guidance to a range of $5.61 to $5.72, which works out to 3.5% to 5.5% growth off last year's base.
JORDAN: Right, but here's the interesting wrinkle — one analyst on the call pointed out that even with that raised low end, it's still below what they delivered in the first half. So the second-half math implies things moderate a bit. CEO Sal Mancuso's answer basically boiled down to: the consumer is still under pressure — elevated gas prices, inflation — and they're stepping up investment behind new launches, so don't expect the same pace of growth to just continue in a straight line.
ALEX: That's a good instinct as a listener — when a company raises guidance but the low end still trails first-half performance, it's worth asking why. In this case it sounds like a mix of planned investment spend and just conservative phasing.
JORDAN: Exactly. Now let's talk about where the real growth engine is: smokeable products. That segment's adjusted operating income grew 4.2% in the first half, with margins expanding to nearly 65%. Cigarette volume declines are actually moderating — down about 5% industry-wide when you adjust for inventory, and that's the fourth straight quarter of that decline rate improving.
ALEX: Why is that happening? Management pointed to something pretty specific — fewer smokers switching over to illicit flavored disposable vapes, largely because of stepped-up enforcement. Federal seizures topped $250 million this quarter alone, plus a Minnesota AG lawsuit against a major illicit vape manufacturer.
JORDAN: Which is a fascinating dynamic — Altria's traditional cigarette business is getting a tailwind from regulators cracking down on unregulated vape products. That's basically the whole thesis of tobacco harm reduction policy playing out in real time, just not in the direction some might expect.
ALEX: Meanwhile, within cigarettes, there's a real trade-down story happening. Discount segment share grew 2.6 points as lower-income consumers feel the pinch. Marlboro held its premium leadership — 59.6% share of premium — but its overall share dipped 1.5 points as some smokers shift to value options.
JORDAN: And Altria's playing both sides of that. They launched Marlboro Cowboy Cut — a value-oriented Marlboro line tied to America's 250th anniversary, clever branding there — while also growing their Basic discount brand, which saw share up 2.3 points year-over-year. Management was clear: the strategy is to participate in discount without accelerating the category's growth, protecting Marlboro's premium position as much as possible.
ALEX: Let's shift to the smoke-free side, because this is where the long-term story lives. The oral tobacco segment actually had a rough quarter on paper — adjusted OCI down 8% — but that's largely due to tough prior-year comparisons and heavy investment behind on! PLUS, their new nicotine pouch line.
JORDAN: Right, and context matters here. Nicotine pouches are now nearly 60% of the enti This episode includes AI-generated content.
AI-generated content
29 JUL 2026 · More earnings analysis: https://betafinch.com
Groups: RETAIL (https://betafinch.com/groups/RETAIL), INCOME (https://betafinch.com/groups/INCOME)
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. Today we're digging into Procter & Gamble's fiscal Q4 and full-year 2026 results — and there's a lot to unpack, from a CEO transition on the board to a fresh look at fiscal 2027 guidance.
But before we get into it, quick disclaimer. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
JORDAN: Alright, so let's start with the news that isn't really about the numbers — Jon Moeller is retiring from the board after 38 years at P&G. He's held basically every top job there: CFO, COO, CEO, Executive Chairman. That's a long goodbye for someone who shaped the company's current structure.
ALEX: Right, and CEO Shailesh Jejurikar spent real time on the call thanking him before handing it to CFO Andre Schulten for the actual numbers. So let's get into those. For the full fiscal year, organic sales grew just over 1%, core EPS came in at $6.89, up about 1%. Not a blowout year, but they hit their guidance ranges despite what they called a "very volatile environment."
JORDAN: And that volatility really showed up in the fourth quarter specifically. Core EPS was $1.43, down 3% year-over-year — on a currency-neutral basis, down 5%. They pointed to a spike in energy, transportation, and material costs, about six cents a share, that was mostly offset by tariff refunds.
ALEX: There was also this interesting wrinkle in the U.S. business — a gap between what's called "sell out" versus "sell in." Basically, consumer purchases at retail — sell out — were up 2%, but P&G's shipments to retailers — sell in — were down 1%. That's a three-point gap.
JORDAN: Yeah, and management explained that pretty clearly — Amazon Prime Day shifted into late June this year instead of early July, which changed how promotional spending got recognized, plus retailers were drawing down inventory. It's a timing issue more than a demand issue, and honestly analysts pushed hard on this exact point during Q&A.
ALEX: They did. One analyst basically asked, "Is this a P&G-specific problem?" And Schulten's answer was pretty blunt — he said it's simply because P&G is bigger and has higher velocity than competitors, so when retailers want to cut inventory fast, they trim the biggest, fastest-moving brand on the shelf. It's math, not strategy failure.
JORDAN: What stood out to me geographically was China. Organic sales there grew 4% for both the quarter and the year, and P&G said they're growing share in China for the first time in 15 quarters. Baby care was the star — they highlighted this premium diaper using silk materials that's delivered double-digit growth for six straight quarters and now has them back as the number one baby care brand in the country.
ALEX: That silk diaper story is a nice example of their broader playbook — figure out what consumers actually want, translate it into product innovation, and let that drive both category growth and share. They gave a bunch of these: Vicks cough and cold in Latin America, Pantene in Germany leaning into influencer marketing, SK-II shifting to lifestyle content on social commerce.
JORDAN: The Tide story was probably my favorite, though. They did the biggest upgrade to original Tide liquid in over two decades — same price, much better performance — and it went from declining sales to high single-digit growth. Jejurikar said flat out it beat their own expectations.
ALEX: And that's really the "stronger core" half of their strategy — fix what you already have. The other half is "bigger more," which is Tide Evo, this new unit-dose detergent with no plastic packaging, built on over 50 patents. National rollout is h This episode includes AI-generated content.
AI-generated content
28 JUL 2026 · More earnings analysis: https://betafinch.com
Groups: RETAIL (https://betafinch.com/groups/RETAIL), INCOME (https://betafinch.com/groups/INCOME)
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Coca-Cola's second quarter 2026 results, and honestly, Jordan, this is a fun one — FIFA World Cup, Marriott winning back after 34 years, a lot going on.
JORDAN: Yeah, it's a loaded quarter. Before we jump in, quick disclaimer.
ALEX: Right — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
JORDAN: Perfect, let's get into it. So headline numbers: organic revenue grew 6%, unit case volume grew 5%. That's a strong beat, but there's a catch.
ALEX: Right, they were cycling an easier comp from last year, plus favorable weather and that huge FIFA World Cup activation. On a two-year average basis, volume growth was actually 2%, which management says is more reflective of the underlying trend.
JORDAN: And that 2% is basically in line with where Coke's been running for years — CFO John Murphy pointed out the industry has grown 3-4% historically, and Coke's long-term algorithm target is 4-6%, with the ambition to be at the high end.
ALEX: Let's talk profitability, because this was arguably the bigger story. Comparable gross margin was up about 120 basis points, operating margin up about 90 basis points. EPS came in at $0.97, up 11%, though two points of that was currency tailwind.
JORDAN: One analyst even called it a potential all-time-record operating margin quarter for Coke. And free cash flow was strong too — about $6.9 billion, up year over year. Balance sheet's in great shape, net debt leverage at 1.4 times EBITDA, well below their 2-2.5x target range.
ALEX: And they raised guidance. Organic revenue growth now expected around 5%, at the high end of prior guidance. Comparable currency-neutral EPS growth bumped up to 7-8%, and all-in comparable EPS growth now guided at 9-10% versus the $3 EPS base in 2025.
JORDAN: Worth noting there's some noise in there — divestitures, mainly the pending sale of Coca-Cola Beverages Africa, are expected to be a 2-3% headwind to revenue and about 1% headwind to EPS. Currency is actually helping this year, flipping from a longtime headwind to roughly a one-point tailwind on revenue and three points on EPS.
ALEX: Now let's talk strategy, because the FIFA World Cup campaign was clearly a centerpiece. CEO Henrique Braun said trademark Coca-Cola grew volume 5% for the quarter — the strongest in 17 years excluding COVID recovery.
JORDAN: And the numbers behind the activation are wild — over 1 billion Panini stickers distributed across 40+ markets, 25 million first-party data points collected, more than 9 billion views generated through digital and social activations. Average incidence at World Cup venues topped 80%, a record.
ALEX: The interesting question from an analyst was basically: was this a one-time sugar high, or does it stick? Management's answer was that the real value is the first-party data and consumer insights carrying forward into future campaigns — things like "Coke and Meals" moments in the second half.
JORDAN: Regionally, North America had a strong quarter — gained value and volume share, grew revenue and profit. Relaunched Mr. Pibb grew volume over 20%, which is a nice example of their innovation engine working. Latin America gained share too, though Mexico remains tough while Brazil's improving.
ALEX: EMEA gained share but profit actually declined due to investment phasing. And Asia Pacific — this got some analyst pushback — operating income declined there as Coke invests heavily in affordability and revenue growth management in India and China to expand the consumer base.
JORDAN: Management framed that as deliberate — playing the l This episode includes AI-generated content.
AI-generated content
22 JUL 2026 · More earnings analysis: https://betafinch.com
Groups: INCOME (https://betafinch.com/groups/INCOME)
──────────
Welcome to Beta Finch, your AI-powered earnings breakdown of the biggest names in the market. Here's the script for PMI's Q2 2026 call.
---
**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. Today we're digging into Philip Morris International's second quarter 2026 results — and there's a lot going on here, including a CFO transition. But first, the standard stuff: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
**JORDAN:** Right, and PMI gave us plenty to unpack. Let's start with the headline numbers, because they were strong.
**ALEX:** Very strong. Organic net revenue growth of +8% for the quarter, operating income up +11%, and adjusted diluted EPS hit $2.20 — that's +14% currency-neutral, +15% in dollar terms. Quarterly net revenue crossed $11 billion for the first time ever.
**JORDAN:** And this wasn't just a currency tailwind story either. Outgoing CFO Emmanuel Babeau flagged that about a third of the EPS beat came from a favorable tax-related currency effect tied to the Russian ruble, but two-thirds was real operating strength — better SG&A phasing and a surprisingly strong combustible business.
**ALEX:** Let's talk about that smoke-free business first, because it's really the engine of this whole story. IQOS adjusted in-market sales volume grew +5% in the quarter — that sounds almost modest until you realize it includes two known headwinds: an excise tax hike in Japan and a flavor ban in Poland.
**JORDAN:** Strip those out and IQOS growth was over 10% in Q2, north of 11% for the first half. That's the real underlying trend. IQOS also just cracked Kantar's list of top 100 most valuable global brands — pretty remarkable for a product that's only a decade old.
**ALEX:** VEEV, their vapor brand, had an absolutely wild quarter — shipments up 55% in Q2, 72% for the half. Management says it's now the number one closed-pod brand in Europe and in global travel retail.
**JORDAN:** Now let's get into the U.S., because this is where investors have been the most impatient. ZYN shipments grew 2% year-over-year to 2.9 billion pouches, and importantly, that's despite lapping an inventory tailwind from last year. Sequentially versus a rough Q1, U.S. net revenue was up 38%, gross profit up 46%.
**ALEX:** The bigger story is the product lineup. They just launched ZYN Ultra — a lower-priced moist variant meant to close the gap with competitors — and they're bringing 1.5 and 8 milligram dry formats in Q3. Babeau was pretty clear-eyed that it's early days, just two weeks of data on Ultra, but the initial read and consumer feedback were encouraging.
**JORDAN:** And there's a regulatory tailwind too — ZYN got Modified Risk Tobacco Product authorization on 20 SKUs, the only nicotine pouch product with that designation. That lets them actually market reduced-risk claims versus cigarettes, which is a real differentiator.
**ALEX:** Here's the strategic pivot that stood out to me: management is choosing to step up U.S. investment hard in the second half — more marketing, a new brand campaign called "When It Clicks," expanded distribution — partly to build ZYN and partly to lay the groundwork for IQOS ILUMA's eventual U.S. launch, pending FDA action.
**JORDAN:** Which is why, despite beating estimates two quarters in a row, PMI held its full-year guidance rather than raising it. An analyst from Goldman actually pushed on this directly, and Babeau basically confirmed: yes, the flat guidance reflects the decision to plow incremental profit back into U.S. investment rather than let it drop straight to the bottom line.
**ALEX:** Let's touch on combustibles too, because cigarettes had a surprisingly strong quart This episode includes AI-generated content.
AI-generated content
21 JUL 2026 · More earnings analysis: https://betafinch.com
Groups: INCOME (https://betafinch.com/groups/INCOME), INDUSTRIALS (https://betafinch.com/groups/INDUSTRIALS)
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're digging into 3M's second quarter 2026 results, and there's a lot to unpack here. Before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
JORDAN: And Alex, this was genuinely a strong quarter for 3M. Organic growth of 5.4%, operating margin at 24.9% — that's their highest ever, by the way — EPS of $2.40, up 11% year-over-year, and free cash flow of $1.3 billion with 107% conversion. That's about as clean a beat as you'll see.
ALEX: Right, and they didn't just beat expectations, they raised guidance across the board. Full-year organic growth guidance moved from 3% to greater than 3.5%. EPS guidance went from $8.50-$8.70 up to $8.80-$8.95. Free cash flow guidance ticked up $100 million to $4.7-$4.9 billion.
JORDAN: What stood out to me is CEO Bill Brown was pretty emphatic this isn't a macro tailwind story. CFO Anurag Maheshwari basically said the same thing on the call — this is internal execution. Commercial excellence initiatives, better sales force effectiveness, cross-selling that's running 40% ahead quarter-over-quarter, and customer attrition improving about 200 basis points, mostly in their Safety & Industrial business.
ALEX: And the innovation piece is a big part of the story too. They launched 92 new products in the quarter, up 44% year-over-year, putting them on pace for more than 350 new products this year. They're targeting over 1,000 new product launches by 2027, and development cycle time is down about 20%.
JORDAN: The segment breakdown really tells the story. Safety & Industrial — that's SIBG — grew 8.2%, with double-digit growth across electrical markets, adhesives and tapes, abrasives, and industrial specialties. Transportation and Electronics grew 5.9%, helped by strength in semiconductors, aerospace, and data centers. But Consumer was the soft spot, down 2.1% for the quarter because of some retailer destocking in late June.
ALEX: Now let's talk about the headline strategic news, because this is the part that got analysts excited. 3M announced a partnership with Microsoft — they're the first hyperscaler to deploy 3M's Expanded Beam Optical technology, or EBO, in Azure data centers.
JORDAN: This is fascinating from a materials science angle. EBO is basically a more durable, dust-resistant fiber optic connector that Brown said can cut installation time in data centers by about 85%. They've got 100 patents already, 50 more pending. Revenue this year is only in the $40-50 million range, but Brown said it could scale 4x or 5x — or more — over the next few years as the broader market shifts from copper to optical.
ALEX: And they're not trying to own the whole ecosystem either. They formed a 44-player multi-supplier agreement across hyperscalers, chip makers, and connector manufacturers. Brown was clear — they won't succeed as a sole provider, this is about industry-wide adoption.
JORDAN: There was also the Madison Fire & Rescue deal — they closed on July 1st, folding it into their Scott SCBA business as a majority-owned joint venture, and picked up $700 million in cash in the process. That JV does about $800 million in revenue, growing high single digits with above-average margins. Classic example of reshaping the portfolio toward higher-growth, higher-margin businesses.
ALEX: One thing I want to flag from the Q&A — China came up, and it's a much better story than a lot of people expected. Double-digit growth in the quarter, about 8% for the first half, and that's the seventh straight quarter of double-digit growth in India specifica This episode includes AI-generated content.
AI-generated content
16 JUL 2026 · More earnings analysis: https://betafinch.com
Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE), INCOME (https://betafinch.com/groups/INCOME)
──────────
Welcome to Beta Finch, your AI-powered earnings breakdown. Here's the Abbott Labs (ABT) Q2 2026 script.
---
**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into Abbott Laboratories' second quarter 2026 results. Before we jump in, quick disclaimer — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
**JORDAN:** Thanks, Alex. And there's a lot to like in this print. Let's start with the headline numbers.
**ALEX:** Right, so Abbott posted sales growth of 4.8% for the quarter — that's an acceleration from the last two quarters — and adjusted EPS of $1.31, which beat both the midpoint of their guidance and consensus estimates.
**JORDAN:** And here's the part investors really zeroed in on — Abbott didn't just reaffirm full-year sales guidance of 6.5% to 7.5%, they actually raised their EPS guidance range to $5.45 to $5.60. CEO Robert Ford was pretty clear that gross margin expansion is doing a lot of the heavy lifting there — margins came in at 58%, up 100 basis points year-over-year.
**ALEX:** Let's talk segments, because there's a real story of divergence here. Medical devices grew 8.5%, led by electrophysiology — that's the heart rhythm and ablation business — which grew in the low teens. EPD, their emerging markets pharma division, grew 9%, powered by India, Latin America, and Southeast Asia.
**JORDAN:** Diagnostics was mixed. Core lab was strong, U.S. up 7.5%. But rapid and molecular diagnostics — that's respiratory testing — declined 8% because it was just a weak flu and respiratory virus season. That's expected and temporary though, not a demand problem.
**ALEX:** And then nutrition — this is the comeback story of the quarter. Sales came in ahead of expectations for the second straight quarter, up sequentially by $125 million. Ensure retail consumption in the U.S. is up double digits.
**JORDAN:** Yeah, that's the price increases from late last year finally working through the system — volumes are responding well now that consumers have adjusted. Management is now framing nutrition as a sustainable 2-4% grower going forward.
**ALEX:** Let's get into the strategic stuff, because there's a lot of pipeline news. Abbott completed enrollment in its coronary IVL trial, filed with the FDA for the Amulet 360 left atrial appendage device, and got a CE mark in Europe for Libre Duo — which is notable, it's the world's first dual glucose-ketone monitoring sensor, designed to help prevent diabetic ketoacidosis.
**JORDAN:** The CGM story is worth sitting with for a second. Diabetes care crossed $2 billion in quarterly sales, growing 9.5%. Now, one analyst on the call kind of poked at that number as "only" 9.5%, and Ford pushed back — reasonably, I'd say. He pointed out there's 75 to 80 million people globally who could realistically use a CGM, and only 15 million currently do. Growth right now is basically waiting on reimbursement expansion, especially the big one: U.S. Type 2 non-insulin Medicare coverage, which could unlock roughly 10 million beneficiaries. Ford said that could happen this fall but wouldn't pin down an exact date.
**ALEX:** They're also planning a fifth manufacturing facility for CGM sensors — a billion-dollar investment — because they expect to hit capacity limits at their current facility within a couple years. That's a pretty strong signal of how bullish they are on long-term demand.
**JORDAN:** One theme that came up repeatedly in the Q&A was this investor worry about decelerating hospital procedure volumes — tied to ACA enrollment changes and Medicaid dynamics. This episode includes AI-generated content.
AI-generated content
15 JUL 2026 · More earnings analysis: https://betafinch.com
Groups: PHARMA (https://betafinch.com/groups/PHARMA), INCOME (https://betafinch.com/groups/INCOME)
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. Today we're digging into Johnson & Johnson's second quarter 2026 results, and Jordan, there's a lot to unpack here.
JORDAN: There really is. But first, the fine print — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
ALEX: Right, so let's get into it. J&J posted $25.3 billion in quarterly sales, up 5.6% operationally. That doesn't sound huge until you realize they absorbed a 460 basis point headwind from STELARA losing patent protection to biosimilars.
JORDAN: Yeah, strip out STELARA and the rest of the business grew double digits. That's the real story. Net earnings came in at $5.5 billion, diluted EPS of $2.27, and on an adjusted basis, EPS was $2.90, up nearly 5% year-over-year. And here's the kicker — they raised full-year guidance. Operational sales growth now expected at 6.5% to 7.1%, and adjusted EPS guidance moved up to $11.50-$11.65.
ALEX: They're also closing in on a milestone — more than $100 billion in annual revenue for the first time in the company's 140-year history.
JORDAN: Which is wild to say out loud. This is a company with 28 different products or platforms each doing over a billion dollars a year. That's not a one-hit-wonder portfolio, that's just breadth everywhere.
ALEX: Let's talk oncology, because that's really where J&J flexed this quarter. DARZALEX, their multiple myeloma drug, did over $4 billion, up almost 18%. But the newer combo therapies are what caught my eye — CARVYKTI up 47.7%, TECVAYLI up 56%, TALVEY up 62.6%.
JORDAN: Those growth rates on top of an already-dominant multiple myeloma franchise are pretty remarkable. And they're not resting — new data showed the TALVEY-DARZALEX combo keeping over 80% of patients progression-free at two years, with overall survival up to 89%. That's the kind of data that extends a franchise's life for years.
ALEX: Then there's the newer launches — ICOTYDE in psoriasis, INLEXZO in bladder cancer, RYBREVANT in lung and now head-and-neck cancer. ICOTYDE in particular is getting a lot of attention. Over 11,000 patients started therapy, 6,000 unique prescribers, and more than half of commercial payers already covering it within 90 days.
JORDAN: What's interesting is how they're positioning it alongside TREMFYA, which by the way had a monster quarter — 71% growth, its first $2 billion quarter. Instead of cannibalizing each other, management's framing ICOTYDE as the go-to first systemic treatment and TREMFYA as the first-choice biologic, especially for patients trending toward psoriatic arthritis. It's a two-pronged attack on the same disease area.
ALEX: Now, MedTech was the softer spot this quarter — only 3.6% growth. Cardiovascular was the drag, mainly Abiomed's heart pump business.
JORDAN: Right, and this is worth unpacking because it wasn't a demand problem. A neutral clinical trial out of the U.K. made physicians more cautious about patient selection for Impella devices, so usage slowed. Management was pretty direct about it — they called it a "behavioral" issue, not structural. They're leaning on their own much larger evidence base, over 40,000 patients studied versus the UK trial's 300, while they wait for their own PROTECT IV trial data, which won't read out until 2027.
ALEX: Meanwhile, three of MedTech's four businesses — surgery, vision, and orthopedics — actually accelerated and beat expectations. So it's really one segment, heart recovery, dragging on an otherwise solid MedTech story.
JORDAN: And there's real excitement building around the robotics pipeline — the OTTAVA surgical robot and MONARCH for urology are both awaiti This episode includes AI-generated content.
AI-generated content
9 JUL 2026 · More earnings analysis: https://betafinch.com
Groups: RETAIL (https://betafinch.com/groups/RETAIL), INCOME (https://betafinch.com/groups/INCOME)
──────────
Welcome to Beta Finch, your AI-powered earnings breakdown of the calls that move markets. Today we're digging into PepsiCo's Q2 2026 results.
ALEX: Hey everyone, welcome back to Beta Finch! I'm Alex, here with Jordan, and today we're breaking down PepsiCo's second quarter 2026 earnings call. This one's got a real tale-of-two-businesses vibe — strong international, choppier North America. Before we dive in, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
JORDAN: Right, and there's a lot to unpack here, Alex. This wasn't a blowout quarter, but it also wasn't a disaster — it's more of a "here's exactly where the pressure points are" kind of call.
ALEX: Let's start with the headline numbers. First-half revenue grew almost 7% company-wide, which is solid. Global volumes were up 3% in foods and 2% in beverages — CEO Ramon Laguarta called that the fastest volume growth since 2022.
JORDAN: And on earnings, reported EPS grew 6% in the first half, constant currency EPS up 3%. They reaffirmed full-year guidance, though CFO Steve Schmitt flagged it might land toward the low end of their EPS range.
ALEX: The story underneath those numbers, though, is really about a split business. International is on fire — set to cross $40 billion this year, growing 7% and accelerating. Meanwhile North America, especially the food business, PFNA, came in softer than expected.
JORDAN: Yeah, PFNA volume was flat in the quarter. And that's notable because PepsiCo spent the first half of the year specifically investing in affordability — lowering prices, portion control packs — to get salty snacks volume growing again after a stretch of decline.
ALEX: And it kind of worked, right? Laguarta made the point that the category went from negative volume to positive, and PepsiCo is actually gaining share within that. So directionally the strategy's working, just not as fast as hoped.
JORDAN: Right, and he was pretty candid about why: gas prices. Rising fuel costs hit convenience and gas station channels hard — those impulse-purchase locations where price sensitivity shows up fast. People are pulling into the pump but not converting that traffic into snack and drink purchases the way they used to.
ALEX: That convenience-and-gas weakness actually shows up directly in the numbers too. PBNA — the North America beverage business — saw operating margin down about 90 basis points. Steve Schmitt broke that into three pieces: about half tied to the Alani Nu commercial arrangement, then the soft convenience-and-gas channel, and product mix.
JORDAN: What I found interesting was management resisting the idea of some big "reset" — a phrase one analyst used. Laguarta pushed back pretty firmly, saying they don't need one because of record productivity gains funding the growth investments.
ALEX: There was also a nice tailwind mentioned — tariff refund claims from last year, expected to add about a full point of EPS growth for the full year. That's helping offset rising commodity costs, particularly some inflation expected in Europe and the Middle East in the back half.
JORDAN: On the international side, it's honestly the highlight of the call. Laguarta did a world tour — Vietnam, Thailand, China, the Middle East, all more resilient than expected despite higher gas prices there too. Europe's getting a real boost from World Cup sponsorship activations. Latin America's a bit softer but still trending positive.
ALEX: And Schmitt added that international operating margin actually grew a full point in the quarter — so it's not just top-line growth, it's profitable, efficient growth.
JORDAN: One thing This episode includes AI-generated content.
Reliable dividend payers popular with income-focused investors. AI-powered earnings call analysis for Income & Dividends (INCOME). Two AI hosts break down quarterly results, key metrics, and market implications in digestible...
show more
Reliable dividend payers popular with income-focused investors. AI-powered earnings call analysis for Income & Dividends (INCOME). Two AI hosts break down quarterly results, key metrics, and market implications in digestible podcast episodes.
show less
Information
| Author | Beta Finch |
| Organization | Nathan hirst |
| Categories | Investing |
| Website | betafinch.com |
| contact@betafinch.com |
Copyright 2026 - Spreaker Inc. an iHeartMedia Company
